IP Library Granted Patent US 7,425,428
Granted Patent B1
US 7,425,428 · App. 08/443,077 · Granted Sep 16, 2008

Recombinant DNA construct for HIV envelope polypeptides and polypeptides produced thereby

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,425,428
App. No.
08/443,077
Granted
Sep 16, 2008
Kind
B1
Abstract

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.

Claims (14)

1. A recombinant DNA construct useful for the expression of a recombinant polypeptide in a cell containing the construct, the construct comprising control sequences which regulate transcription and translation of the recombinant polypeptide in the cell and a coding sequence regulated by the control sequences, wherein the coding sequence comprises a DNA sequence of at least about 27 bp of the env open in reading frame shown in FIG. 4 characterized in that the DNA sequence encodes an antigenic env HIV amino acid sequence which amino acid sequence is immunologically non-cross-reactive with HTLV-I and HTLV-II.

2. A recombinant DNA construct according to claim 1 comprises a replication system functional in a eukaryotic cell.

3. A recombinant DNA construct according to claim 1 comprises a replication system functional in a yeast cell.

4. A recombinant DNA construct according to claim 1 comprises a replication system functional expression in a bacterial cell.

5. A recombinant DNA construct according to claim 1 wherein the DNA sequence encodes a complete env polypeptide.

6. A cell comprising a recombinant DNA construct according to any one of claims 1 to 4 or 5 , wherein the cell expresses the antigenic HIV amino acid sequence and is free from other cells which do not express the antigenic HIV amino acid sequence.

7. A recombinant antigenic env HIV polypeptide produced by the construct of claim 2 expressed in an eukaryotic cell.

8. A recombinant antigenic env HIV polypeptide produced by the construct of claim 3 expressed in a yeast cell.

9. A recombinant antigenic env HIV polypeptide produced by the construct of claim 4 expressed in a bacterial cell.

10. A recombinant antigenic env HIV polypeptide produced by the DNA construct of claim 5 .

11. The recombinant antigenic env HIV polypeptide of claim 10 which is not glycosylated.

12. A purified polynucleotide of at least about 27 bp of the env open reading frame shown in FIG. 4 , characterized in that the DNA sequence encodes an antigenic env HIV-I amino acid sequence which amino acid sequence is immunologically non-cross-reactive with HTLV-I and HTLV-II.

13. The polynucleotide according to claim 12 which comprises the complete env open reading frame shown in FIG. 4 .

14. A recombinant antigenic env HIV polypeptide produced by the construct of claim 1 expressed in an eukaryotic cell.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE AND ASSIGNOR. PREVIOUSLY RECORDED ON REEL 033886 FRAME 0313. ASSIGNOR(S) HEREBY CONFIRMS THE CONFIRMATORY ASSIGNMENT. Recorded Oct 20, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 034116/0974 →
CONFIRMATORY ASSIGNMENT Recorded Oct 2, 2014
From: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.; NOVARTIS AG; GRIFOLS WORLDWIDE OPERATIONS LIMITED
Reel/Frame 033886/0313 →
CHANGE OF NAME Recorded Mar 27, 2008
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 020715/0212 →
MERGER Recorded Nov 16, 2006
From: NOVARTIS BIOTECH PARTNERSHIP, INC.
To: CHIRON CORPORATION
Reel/Frame 018525/0844 →